Skin Laboratory PCL (SKIN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Skin Laboratory PCL stock THB 1.02, price THB 0.78, upside +30.8%, quality 60 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
13‑month range 0.7800 THB – 3.62 THB · fair‑value band 0.8700 THB – 1.18 THB · the 0.7800 THB price screens below the 1.02 THB fair value. As of Nov 7, 2026.
Follow Skin Laboratory PCL in your weekly email
Every Wednesday you see whether Skin Laboratory PCL is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Skin Laboratory Public Company Limited manufactures and distributes beauty products in Thailand and internationally. The company offers skincare products, beauty creams, cosmetics, and dietary supplements under the Skinsista and Dermie brand names.
Show moreShow less
It sells its products through online channels and stores. The company was incorporated in 2013 and is headquartered in Nonthaburi, Thailand.
Stock analysis
Skin Laboratory PCL (SKIN) currently trades at 0.7800 THB, while our model-based Fair Value estimate is 1.02 THB, implying the stock looks roughly 24% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 1.27 THB per share, and 16 of the 24 models we run sit above the 0.7800 THB price.
Bear case: the Growth Earnings group reads lowest at 0.4800 THB, and 8 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.8700 THB (bear) to 1.18 THB (bull), the price of 0.7800 THB sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Skin Laboratory PCL reported revenue of 177M THB in FY2025 versus 282M THB in FY2022, a compound −14.4%/yr. Reported net income was 4.4M THB in FY2025, compounding −25.8%/yr from FY2022.
Key figures
Market cap 116M THB (≈ $3.5M) Micro · P/S ratio 0.81 · EPS (TTM) −0.1400 THB · Dividend yield 13.5% · Net margin −11.9% · Return on equity −24.3% · Return on assets (EBIT) 13.3% (4-year average) · Operating margin −22.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 19 out of 100 (low confidence).
What moves the price
The share trades about 55% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at 31%, SKIN screens cheaper than that median.
Fair Value models
Bear0.8700 THBFair Value 1.02 THBBull1.18 THB
Price 0.7800 THB · Upside +30.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−22.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.4%
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in THB ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−18.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−31.6%
Dividend (yield on the price)13.5%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 3%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−21.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Thailand: IMF forecast 1.2% a year to 2030, 1.1% from 2016 to 2025) that is about −22.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+30.8% · Above median
Profitability
Return on assets3.5% · Below median
Net margin (12 months)−11.9% · Bottom 25%
Operating margin (12 months)−22.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−34.3% · Bottom 25%
Dividend yield (12 months)13.5% · Top 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Skin Laboratory PCL (SKIN) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 1.02 THB versus a price of 0.7800 THB, about +31% upside (undervalued).
What is the fair value of SKIN?
Our model-based fair value for Skin Laboratory PCL is 1.02 THB (as of Nov 7, 2026), built from audited fundamentals. The current price: 0.7800 THB.
What is the quality score of SKIN?
Skin Laboratory PCL has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Skin Laboratory PCL (SKIN)?
Our model-based price target is the fair value of 1.02 THB (as of Nov 7, 2026) from 24 valuation models. Cautious scenario 0.8700 THB, optimistic scenario 1.18 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Skin Laboratory PCL stock forecast for 2026?
Our models put fair value at 1.02 THB, about +31% upside versus a price of 0.7800 THB (undervalued). Cautious scenario 0.8700 THB, optimistic scenario 1.18 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Skin Laboratory PCL (SKIN)?
Skin Laboratory PCL reported trailing-twelve-month revenue of about 151M THB (latest available figure, as of Nov 7, 2026).
Does Skin Laboratory PCL pay a dividend?
Skin Laboratory PCL currently shows a dividend yield of 13.48% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Skin Laboratory PCL (SKIN)?
Skin Laboratory PCL has a dividend yield of 13.5%.
What growth is priced into Skin Laboratory PCL (SKIN)?
For today's price to be fair in a discounted-cash-flow model, Skin Laboratory PCL would have to grow free cash flow by -21.0 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew -14.4 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of SKIN use?
Our models discount Skin Laboratory PCL at 11.6 %: a base by market capitalisation (nano), country premium for Thailand. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Skin Laboratory PCL that is -21.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Skin Laboratory PCL (SKIN) delivered so far?
Over the past 3 years revenue at Skin Laboratory PCL grew -14.4 % a year. The price currently implies free-cash-flow growth of -21.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Skin Laboratory PCL (SKIN) growing?
The median revenue growth in the sector is +2.0 % a year. That is the yardstick for the growth priced into Skin Laboratory PCL (-21.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Skin Laboratory PCL (SKIN)?
The free-cash-flow yield on the price is 11.09 %: that much free cash flow Skin Laboratory PCL produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Skin Laboratory PCL (SKIN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Skin Laboratory PCL it is 1.02 THB per share (as of Nov 7, 2026), against a price of 0.7800 THB. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Skin Laboratory PCL stock overvalued or undervalued in 2026?
As of Nov 7, 2026, SKIN trades below its calculated fair value: price 0.7800 THB, fair value 1.02 THB, a gap of about +31% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SKIN?
No. The price is what the market pays today (0.7800 THB); the fair value is what the company's own numbers justify (1.02 THB). For Skin Laboratory PCL the two are 0.2400 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Skin Laboratory PCL worth?
The market values Skin Laboratory PCL at about 116M THB (market capitalisation, as of Nov 7, 2026). Per share that is 0.7800 THB; our models calculate a fair value of 1.02 THB per share.
What do the bullish and bearish scenarios say about SKIN?
Our models span a range for Skin Laboratory PCL: cautious scenario 0.8700 THB, base 1.02 THB, optimistic 1.18 THB per share (as of Nov 7, 2026, price 0.7800 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Skin Laboratory PCL (SKIN)?
Balance-sheet figures for Skin Laboratory PCL (as of Nov 7, 2026): return on equity −24.3%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is SKIN from its 52-week high?
Skin Laboratory PCL trades at 0.7800 THB, about 55% below its 52-week high of 1.73 THB and at the low of 0.7800 THB (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1.02 THB is for.
Which stocks are comparable to Skin Laboratory PCL?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Skin Laboratory PCL stock attractive at the current price?
The data as of Nov 7, 2026: price 0.7800 THB, calculated fair value 1.02 THB (+31%), Quality Score 60/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SKIN calculated?
We run Skin Laboratory PCL through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 1.02 THB builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Skin Laboratory PCL currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Skin Laboratory PCL (SKIN)?
The closing price on Nov 6, 2026 was 0.7800 THB. Our model-based fair value is 1.02 THB, about +31% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Skin Laboratory PCL right now?
The price is below even our cautious bear case (0.8700 THB). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Skin Laboratory PCL
How large is the market capitalisation of Skin Laboratory PCL (SKIN)?
The market capitalisation of Skin Laboratory PCL is 116M THB (≈ $3.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Skin Laboratory PCL (SKIN)?
The price-to-sales ratio of Skin Laboratory PCL is 0.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Skin Laboratory PCL (SKIN)?
Earnings per share at Skin Laboratory PCL are −0.1400 THB. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Skin Laboratory PCL (SKIN)?
The dividend yield of Skin Laboratory PCL is 13.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Skin Laboratory PCL (SKIN)?
The net margin of Skin Laboratory PCL is −11.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Skin Laboratory PCL (SKIN)?
The return on equity (ROE) of Skin Laboratory PCL is −24.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Skin Laboratory PCL (SKIN)?
On an EBIT basis the return on assets of Skin Laboratory PCL is 13.3% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Skin Laboratory PCL (SKIN)?
The operating margin of Skin Laboratory PCL is −22.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Skin Laboratory PCL (SKIN)?
Revenue at Skin Laboratory PCL is growing −34.3% versus a year earlier (3y avg −14.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
Free · no account needed
Watch Skin Laboratory PCL in the live analysis
One click puts Skin Laboratory PCL on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026